RxDoctor Payments Data

Clement Eiswirth, MD

Advanced Heart Failure and Transplant Cardiology · New Orleans, LANPI 1477538726

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $226,631 of the $277,116 with a category attached, or 81.8%. 21 manufacturers reported payments, led by Pfizer at 31.4% of the total. Reporting peaked in 2019 at $77,518 and has fallen 85.4% since, to $11,336 in 2025.

$277,116in general payments, 2019–2025

Across 368 payments — averaging $753.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$87K
  • E.r. Squibb & Sons, L.L.C.$67K
  • Alnylam Pharmaceuticals Inc.$61K
  • Akcea Therapeutics, Inc.$35K
  • Novartis$14K
  • Bridgebio Pharma, Inc.$11K
  • plus $2K from 15 others
$164,161in research payments, 2019–2025

Across 23 payments — averaging $7137.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$76K
  • Pfizer$39K
  • Alnylam Pharmaceuticals Inc.$27K
  • Amgen$22K

What the payments were for

  • Consulting fees$16,0956%
  • Speaking & faculty fees$226,63182%
  • Travel & lodging$25,5479%
  • Food & beverage$8,7763%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$35,047
Medicare patients
169
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis315$6,888,277
WainuaEplontersen Sodium39$1,576,586
CamzyosMavacamten79$649,302
EntrestoSacubitril/Valsartan359$299,856
EliquisApixaban143$113,435
JardianceEmpagliflozin112$96,191
FarxigaDapagliflozin Propanediol63$54,934
Repatha SureclickEvolocumab77$45,428
Ambrisentan14$39,900
Mycophenolate Mofetil39$4,313
Metoprolol Succinate244$4,105
Sirolimus14$3,844
Potassium Chloride174$3,188
Bumetanide60$2,553
Isosorbide Dinitrate32$1,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$86,903$7,001,712458 claims
AstraZenecaWainua, Farxiga$62$1,631,521102 claims
E.r. Squibb & Sons, L.L.C.Camzyos$67,244$649,30279 claims
NovartisEntresto$13,871$299,856359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →